EU Health Commissioner Dalli’s Resignation Leaves Unfinished Business For Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
John Dalli has resigned following allegations of fraud, bringing to an end a successful, but controversial career, and leaving the future of a number of legislative programs he championed – including anti-counterfeiting, risk assessments and biosimilar reviews – up in the air.
You may also be interested in...
Time Is Running Out For Revised EU Clinical Trials Legislation
A compromise has not been reached yet by EU stakeholders on the new Clinical Trials Directive, but unless one emerges soon, the legislation will be dead.
EU Health Commissioner Candidate Remains Question Mark For Pharma
The European Parliament has voted in favor of Maltese Foreign Minister Tonio Borg’s candidacy for the vacant EU health commissioner post despite his lack of health policy experience.
EU Device Reform Proposal Adds More Government Scrutiny, But No FDA-Like Review Body
The recommendation attracting the most concern from industry: a new Medical Device Coordination Group that would have the option to scrutinize third-party pre-market assessment reports for select devices prior to marketing.